OSE Immunotherapeutics - Anticipation builds with positive OSE-279 data
At the AACR-NCI-EORTC conference in Boston, OSE presented the initial positive data supporting the potential efficacy of its anti-PD1 monoclonal...
422 Views
OSE Immunotherapeutics - Maintaining momentum after an active H123
OSE Immunotherapeutics (OSE) has announced its H123 results, providing an operational and a financial update. Highlights from the period included...
344 Views
OSE Immunotherapeutics - Publication puts Tedopi back in the spotlight
OSE has announced that the results from its Phase III trial (ATALANTE-1) for Tedopi have been published in Annals of Oncology. While the study...
531 Views
OSE Immunotherapeutics - Grant to weave RNA into R&D platform
OSE Immunotherapeutics (OSE) has announced that it has received grant innovation funding of €200,000 from the French government and Region Pays de...
405 Views
OSE Immunotherapeutics - Lusvertikimab progressing on multiple fronts
OSE has announced that Lusvertikimab (or OSE-127), the company’s most advanced asset in the immuno-inflammation space, has received a positive...
297 Views